Transcriptomics

Dataset Information

0

Eμ-TCL1xMyc Mice as a Therapeutic Model of Accelerated B-cell Malignancy


ABSTRACT: Richter’s syndrome (RS) is an aggressive B-cell lymphoma arising from chronic lymphocytic leukemia (CLL). RS patients are generally unresponsive both to conventional and B-cell receptor-targeted agents such as ibrutinib. Mouse models that mimic the biology and therapeutic response of RS are lacking, which hampers the development of alternative treatment strategies urgently needed to improve the dismal outcome of RS patients. Aberrant Myc expression is a major factor of RS pathogenesis. To investigate Myc overexpression in the context of CLL, we generated Eµ-TCL1 mice with B-cell restricted Myc expression. Eµ-TCL1xMyc mice uniformly developed highly aggressive lymphoid disease with histologically and immunophenotypically distinct concomitant CLL and B-cell lymphoma, leading to a significantly reduced lifespan. Injection of cells from diseased Eμ-TCL1xMyc into WT mice established a disease similar to that in double-transgenic mice. Both Eμ-TCL1xMyc mice and mice with disease after adoptive transfer failed to respond to ibrutinib. Effective and durable disease control was however observed by selective inhibition of nuclear export protein exportin-1 (XPO1) using a compound currently in clinical development for relapsed/refractory malignancies, including CLL and lymphoma. Altogether, the Eµ-TCL1xMyc mouse model represents a new preclinical tool for experimental drug testing of aggressive lymphoma in the context of CLL, mimicking clinical behavior and therapeutic responses seen in RS patients.

ORGANISM(S): Mus musculus

PROVIDER: GSE129515 | GEO | 2019/07/11

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-02-25 | PXD017457 | Pride
2021-06-27 | GSE178959 | GEO
2024-12-10 | PXD053512 | Pride
2024-12-10 | PXD037314 | Pride
2014-12-31 | E-MTAB-2774 | biostudies-arrayexpress
2024-10-29 | GSE215414 | GEO
2022-12-07 | GSE183429 | GEO
2022-12-07 | GSE183427 | GEO
2022-12-07 | GSE205704 | GEO
2022-12-07 | GSE183426 | GEO